Athersys (NASDAQ:ATHX) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHXGet Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

ATHX stock opened at $0.01 on Friday. Athersys has a 1 year low of $0.01 and a 1 year high of $1.99. The firm has a market capitalization of $317,235.66, a P/E ratio of 0.00 and a beta of -0.90.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.